Article

Dr. Noel G. Boyle Discusses Benefits of Dabigatran Versus Warfarin for Treatment of Atrial Fibrillation

Dr. Noel G. Boyle, Professor of Medicine, Ronald Reagan UCLA Medical Center, Los Angeles, talks about new medications that can work as alternatives to warfarin for atrial fibrillation patients who are at risk for stroke.

In addition, Dr. Boyle discusses the benefits of dabigatran (Brand name: Pradaxa) versus warfarin for the treatment of patients with atrial fibrillation. According to Dr. Boyle, advantages of dabigatran include no patient monitoring, fixed dosing, and less drug interactions. Disadvantages of dabigatran include twice daily dosing and no easy method for monitoring, according to Dr. Boyle.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Rayan Salih, MD, Northeast Georgia Health System
Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, Mount Sinai Fuster Heart Hospital
Varsha Tanguturi, MD, MPH, Mass General Hospital
 Khush Kharidia, MD, UT Southwestern
Alexandra M. Trevino, MD, Northwestern Medicine
AJMC interview with Ali Shan Hafeez and Dr Abdul Rafae Faisal | Background image credit: ipopba - stock.adobe.com
Marry Vuong, PharmD, BCPPS
Julia Rotow, MD, Dana-Farber
Marry Vuong, PharmD, BCPPS
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo